Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
A phase 3 trial of Priovant's brepocitinib has hit its primary endpoint, setting the Roivant biotech up to seek approval for the TYK2/JAK1 inhibitor.
Nick Paul Taylor
Sep 17, 2025 7:00am
PMV plots ovarian cancer filing after seeing midphase data
Sep 10, 2025 9:40am
Atom claims ph. 3 win shows gout drug can beat competition
Sep 8, 2025 9:01am
Takeda, Alkermes lift lid on narcolepsy rivals as race heats up
Sep 8, 2025 6:47am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Amgen looks to level up clinical trials with Veeva pact
Sep 2, 2025 3:05pm
